SARS-CoV-2 Antibodies and Antigens

InVivo has developed a large set of reagents for COVID-19 research and industrial-scale manufacturing of highly sensitive in vitro diagnostics kits. Our portfolio comprises different recombinant versions of the SARS-CoV-2 Spike protein, that were transiently expressed in our high-yielding mammalian HEK cells. These include the full-length Spike protein, the two functional subunits S1 and S2, plus the S1 receptor-binding domain (RBD). The antigens display great activity and proper glycosylation and are suitable for the development of highly sensitive immunoassays. To cater to long-term demand of bulk quantities in the gram scale, InVivo offers recombinant Spike antigen production from stable CHO cell pools. The portfolio was recently expanded by several mutant Spike antigens of the recently discovered variants from UK, South Africa and Brazil. These antigens were produced via transient expression in our proprietary HEK system. Additionally, we offer the SARS-CoV-2 Nucleocapsid protein from bacterial expression systems for research use as well. For industry-scale manufacturing of SARS-CoV-2 detection kits (ELISA, Lateral Flow and more), InVivo provides different monoclonal antibodies from mouse hybridoma, which target the SARS-CoV-2 Spike or Nucleocapsid proteins, respectively. All Spike protein antibodies were validated by ELISA and demonstrate specificity for either the S1-subunit or the RBD region. Humanized chimeric recombinant antibodies targeting the Spike protein are still in development and will be available soon.
A) Schematic overview of the SARS-CoV-2 Spike (S) protein and its functional domains. The S protein plays a crucial role in the infection process and is therefore a great target for the development of diagnostic assays. It is comprised of two subunits: S1 and S2. The S1-subunit (aa 1-681) enables binding of the virion to the ACE2 receptor on the host cell membrane which initiates the infection. It contains an N-terminal signal peptide and the receptor-binding domain (RBD; aa 319-541) highlighted in grey. The S2-subunit (aa 685-1273) contains a C-terminal transmembrane domain (TMD) and an endodomain. It mediates the fusion of the virion with the cellular membranes. The process of membrane fusion depends on S protein cleavage (Furin cleavage site, aa 682-685) leading to the activation of the S protein during infection.
A) Schematic overview of the SARS-CoV-2 Spike (S) protein and its functional domains. The S protein plays a crucial role in the infection process and is therefore a great target for the development of diagnostic assays. It is comprised of two subunits: S1 and S2. The S1-subunit (aa 1-681) enables binding of the virion to the ACE2 receptor on the host cell membrane which initiates the infection. It contains an N-terminal signal peptide and the receptor-binding domain (RBD; aa 319-541) highlighted in grey. The S2-subunit (aa 685-1273) contains a C-terminal transmembrane domain (TMD) and an endodomain. It mediates the fusion of the virion with the cellular membranes. The process of membrane fusion depends on S protein cleavage (Furin cleavage site, aa 682-685) leading to the activation of the S protein during infection.

SARS-CoV-2 Pipeline – ANTIGENS

Product-IDDescriptionStatus
NP_E.coliRecombinant Nucleocapsid (N) protein (aa 1–419) with C-terminal deca-His-Tag, expressed in E. coli BL21(DE3). 1-step purification via affinity chromatography (AC) to a purity of ≥90%.

Product Information

Available
S1-RBD_CHORecombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, stably expressed in CHO cell pools. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥​ 90%.

Product Information

Available
Soluble Spike_CHORecombinant soluble Spike protein (aa 14-1213) stably expressed in CHO cell pools. The soluble Spike contains a mutated polybasic/ furin cleavage site, and mutations K986P/V987P for stabilization of the trimer. The C-terminal TMD and endodomain were replaced by a thrombin cleavage site, a trimerization site and a C-terminal hexa-His-Tag. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD_HEKRecombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-Subunit_HEKRecombinant Spike protein S1-subunit (aa 14-681), transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-Subunit-Fc_HEKRecombinant Spike protein S1-subunit (aa 14-681) with C-terminal Fc-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S2-Subunit-Fc_HEKRecombinant Spike protein S2-subunit (aa 685-1213; excluding TMD and endodomain) with C-terminal Fc-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
Soluble Spike_HEKRecombinant soluble Spike protein (aa 14-1213) transiently expressed in InVivo’s proprietary optimized HEK-INV cells. The soluble Spike contains a mutated polybasic/ furin cleavage site, and mutations K986P/V987P for stabilization of the trimer. The C-terminal TMD and endodomain were replaced by a thrombin cleavage site, a trimerization site and a C-terminal hexa-His-Tag. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available

SARS-CoV-2 Pipeline – MUTANT SPIKE ANTIGENS

Throughout the COVID-19 pandemic, several genetic variants of SARS-CoV-2 have emerged worldwide, which are classified as so-called variants of concern (VOC) or variants of interest (VOI). Amongst other things, there is evidence for an increased transmissibility of these virus variants and a significant reduction of neutralization through existing antibodies. Many mutations affect the Spike protein and its receptor binding domain (RBD).

To investigate the influence of these mutations on the effectiveness of SARS-CoV-2 diagnostics, InVivo offers a series of mutant Spike antigens that were transiently expressed in high yielding mammalian HEK cells. These include several RBD mutants, such as the Alpha variant (B.1.1.7) with or without additional immune-escape mutation E484K, the Beta variant (B.1.351), the Gamma variant (B.1.1.28.1 / P.1), the Delta variant (B.1.617.2) and the Kappa variant (B.1.617.1).

Furthermore, the full-length S-protein mutant of the Alpha variant is available, as well as a stabilized hexa-Pro mutant,

All antigens were produced under serum-free conditions in high-yielding HEK cells (InVEST). The antigens include a C-terminal poly-histidine-tag and were purified via affinity chromatography (AC) and preparative SEC (for polishing) to obtain purity > 90%. The protein activity was validated through an in-house SARS-CoV-2 IgG ELISA.

 

Product-IDDescriptionStatus
Spike-Alpha (B.1.1.7)_HEK

Spike protein of emerging Alpha B.1.1.7 SARS-CoV-2 VOC-202012/01 (HV 69-70 del, Y144 del, N501Y, A570D, P681H, T716I, S982A, D1118H). Protein design and manufacturing process is based on InVivo’s “Soluble Spike” protein (aa 14-1213). The C-terminal TMD and endodomain were replaced by a TEV cleavage site, a trimerization site and a C-terminal deca-His-Tag. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
Spike_HexaPro-Alpha (B.1.1.7)_HEK

S-protein of SARS-CoV-2 variant Alpha (B.1.1.7); mutations HV 69-70 del, Y144 del, N501Y, A570D, P681H, T716I, S982A, D1118H; with additional mutations F817P, A892P, A899P, A942P, K986P, V987P (HexaPro) for stabilization of the protein, according to Hsieh et al.2020. Protein design and manufacturing process is based on InVivo’s “Soluble Spike” protein (aa 14-1213) with octa-His-tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

In Development
S1-RBD-Alpha (B.1.1.7)_HEK

RBD of emerging Alpha B.1.1.7 SARS-CoV-2 VOC-202012/01; mutation N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-Alpha (B.1.1.7)+E484K_HEK

RBD of emerging Alpha B.1.1.7 SARS-CoV-2 variant with additional immune-escape mutation E484K, N501Y VOC-202102/02. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-Beta (B.1.351)_HEK

RBD of emerging Beta B.1.351 SARS-CoV-2 variant; mutations K417N, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-Gamma (P.1)_HEK

RBD of emerging Gamma P.1 SARS-CoV-2 variant; mutations K417T, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
 
S1-RBD-Kappa (B.1.617.1)_HEK

RBD of emerging Kappa B.1.617.1 SARS-CoV-2 Variant of Interest VOC-21APR-01; mutations L452R, E484Q. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-Delta (B.1.617.2)_HEK

RBD of emerging Delta (B.1.617.2) SARS-CoV-2 variant; mutations L452R, T478K. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD_Delta-Plus (AY.1/AY.2)_HEK

RBD of emerging Delta-Plus (AY.1/AY.2) SARS-CoV-2 variant; mutations L452R, T478K, K417N. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-Lambda (C.37)_HEK

RBD of Lambda C.37 SARS-CoV-2 variant; mutations L452Q, F490S. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available

S1-RBD-Eta (B.1.525)_HEK

 

RBD of Eta (B.1.525) SARS-CoV-2 variant; mutation E484K. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available

S1-RBD-Mu (B.1.621)_HEK

 

RBD of Mu B.1.621 SARS-CoV-2 variant; mutations R346K, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

In Development

SARS-CoV-2 Pipeline – ANTIBODIES

For industry-scale manufacturing of SARS-CoV-2 detection kits (ELISA, Lateral Flow and more), InVivo provides a set of different monoclonal IgG antibodies from mouse hybridoma, which selectively target either the SARS-CoV-2 Spike protein (S) or the Nucleocapsid protein (NP). The antibodies were produced from hybridoma under serum-free conditions and purified via Protein-A affinity chromatography to a purity > 90%. All antibodies were validated by ELISA and some of them are specifically recommended for Sandwich-ELISAs or neutralization assays. In addition to monoclonal antibodies from mouse hybridoma, InVivo also offers recombinant, chimeric antibodies containing mouse variable domains (VL+VH) fused with human IgG1 (CH) and kappa (CL) constant domains. The recombinant antibodies were produced under serum-free conditions in high-yielding HEK cells and purified via Protein-A affinity chromatography to obtain purity > 90%.
DescriptionProduct-IDSpecificityHostClonalityIsoptypeSubclassApplication
Anti-Spike (RBD) Antibody

Product Information

AK3398RBDMouseMonoclonalIgGmIgG1κELISA

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3399RBDMouseMonoclonalIgGmIgG2bκELISA Sandwich-ELISA AK3426+AK3399

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3400RBDMouseMonoclonalIgGmIgG2bκELISA

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3401RBDMouseMonoclonalIgGmIgG2bκELISA

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3402RBDMouseMonoclonalIgGmIgG2bκELISA

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3403RBDMouseMonoclonalIgGmIgG1κELISA Sandwich-ELISA AK3427+AK3403

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3404RBDMouseMonoclonalIgGmIgG1κELISA Sandwich-ELISA AK3404+AK3429 AK3404+AK3423

Immunoblot

Anti-Spike (S1) Antibody

Product Information

AK3422 S1MouseMonoclonalIgGmIgG2aκELISA Sandwich-ELISA AK3426+AK3422 AK3427+AK3422

Immunoblot

Anti-Spike (S1) Antibody

Product Information

AK3423S1MouseMonoclonalIgGmIgG1κELISA Sandwich-ELISA AK3404+AK3423

Immunoblot

Anti-Spike (S1) Antibody

Product Information

AK3424S1MouseMonoclonalIgGmIgG2bκELISA

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3426RBDMouseMonoclonalIgGmIgG1κELISA Sandwich-ELISA AK3426+AK3399

Immunoblot

Anti-Spike (RBD) Antibody

Product Information

AK3427RBDMouseMonoclonalIgGmIgG1κELISA Sandwich-ELISA AK3427+AK3403 AK3427+AK3422

Immunoblot

Anti-Spike (S1) Antibody

Product Information

AK3429S1MouseMonoclonalIgGmIgG1κELISA Sandwich-ELISA AK3404-AK3429

Immunoblot

Anti-NP Antibody

Product Information

AK3432NPMouseMonoclonalIgGmIgG1ELISA Sandwich-ELISA
Anti-NP Antibody

Product Information

AK3433.1NPMouseMonoclonalIgGmIgG2bELISA Sandwich-ELISA
Anti-NP Antibody

Product Information

AK3454NPMouseMonoclonalIgGmIgG1κELISA
Anti-NP Antibody

Product Information

AK3455NPMouseMonoclonalIgGmIgG2aκELISA
Anti-NP Antibody

Product Information

AK3456NPMouseMonoclonalIgGmIgG2aκELISA
Anti-NP Antibody

Product Information

AK3457NPMouseMonoclonalIgGmIgG2aκELISA
Anti-NP Antibody

Product Information

AK3458NPMouseMonoclonalIgGmIgG1κELISA
Anti-NP Antibody

Product Information

AK3459NPMouseMonoclonalIgGmIgG1κELISA
Anti-Spike (RBD) rec Antibody

Product Information

RP_SZ_824RBDMammalianNAHuman IgGhIgG1κELISA

Immunoblot

Anti-Spike (S1) rec Antibody

Product Information

RP_SZ_827S1MammalianNAHuman IgGhIgG1κELISA

Immunoblot

SARS-CoV-2 Pipeline – Recombinant ACE2 Proteins

Angiotensin-converting enzyme 2 (ACE2) is a zinc-containing metalloenzyme, which regulates blood pressure through proteolysis of Angiotensin II. ACE2 also serves as an entry point into the cells for different coronaviruses, including SARS-CoV-2. Using the Spike protein RBD which protrudes from the viral membrane surface, the virus binds to the peptidase domain (PD) of ACE2, thereby initiating the infection process. The collectrin-like domain (CLD) is responsible for the homo-dimerization of ACE2. InVivo offers a recombinant form of the full-length ACE2 ectodomain, as well as the ACE2-PD produced in high-yielding HEK cells.
Product-IDDescriptionStatus
ACE2_HEK

Recombinant ACE2 (aa 1-740) with native signal peptide and the entire extracellular domain (including PD and CLD). The protein contains a C-terminal hexa-His-tag and is produced under serum-free conditions in HEK cells. Purification via Affinity Chromatography (AC) to a purity ≥ 90%.

Product Information

Available
ACE2-PD_HEK

Recombinant ACE2 (1–615) with native signal peptide and PD (excluding CLD). The protein contains a C-terminal hexa-His-tag and is produced under serum-free conditions in HEK cells. Purification via Affinity Chromatography (AC) to a purity ≥ 90%.

Product Information

Available

InVivo also offers custom solutions for the production of other Coronavirus antigens. If none of the products mentioned above are of your interest, please reach out to us and learn about production capacities and timelines for your protein of choice.

Contact Us

Invivo Biotech Services

Neuendorfstr. 24a
16761 Hennigsdorf
Germany

email_subscribe_callback

GDPR

4 + 15 =